Diabetes Care, Vol 18, Issue 8 1156-1159, Copyright © 1995 by American Diabetes Association

ARTICLES

1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM

M Kishimoto, Y Yamasaki, M Kubota, K Arai, T Morishima, R Kawamori and T Kamada
First Department of Medicine, Osaka University School of Medicine, Japan.

OBJECTIVE--To evaluate the usefulness of plasma 1,5-anhydro-D-glucitol (1,5-AG) as a possible marker for daily glycemic excursion, we measured plasma 1,5-AG, HbA1c, fasting plasma glucose (FPG) level, and daily excursion of glycemia, from which the M-value (after Schlichtkrull) was calculated as an index of daily glycemic excursion. RESEARCH DESIGN AND METHODS--The subjects were 76 patients with well-controlled non-insulin-dependent diabetes mellitus (NIDDM) treated with diet therapy only (diet, n = 17), oral hypoglycemic agents (OHA, n = 28), conventional insulin therapy (CIT, n = 16), or multiple insulin injection therapy (MIT, n = 15). RESULTS--HbA1c values were similar among all the groups (diet, 6.9 +/- 0.6; OHA, 7.2 +/- 0.5; CIT, 7.1 +/- 0.6; MIT, 7.2 +/- 0.5%). The MIT group showed a significantly higher 1,5-AG concentration (11.5 +/- 5.3 micrograms/ml), a significantly lower M-value (9.2 +/- 5.2), and little risk of hypoglycemia ( < 4 mmol/l) and hyperglycemia ( > 10 mmol/l) (1.3 +/- 1.1 times/24 h) compared with the CIT group (6.9 +/- 3.3 micrograms/ml, 15.7 +/- 8.9, 2.2 +/- 1.6 times/24 h, respectively). Insulin doses (22.4 +/- 4.5 vs. 22.0 +/- 8.9 U/day), FPG (6.6 +/- 2.2 vs. 7.4 +/- 2.4 mmol/l), and HbA1c concentrations were not significantly different between the CIT and MIT groups. M-values significantly correlated with 1,5-AG concentrations (r = 0.414, P < 0.05), but not with HbA1c concentrations. CONCLUSIONS--The findings suggest that the plasma 1,5-AG concentration can be a useful index of the daily excursion of blood glucose, especially in patients with well-controlled NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. M. Dungan, J. B. Buse, J. Largay, M. M. Kelly, E. A. Button, S. Kato, and S. Wittlin 1,5-Anhydroglucitol and Postprandial Hyperglycemia as Measured by Continuous Glucose Monitoring System in Moderately Controlled Patients With Diabetes. Diabetes Care, June 1, 2006; 29(6): 1214 - 1219. [Abstract] [Full Text] [PDF]

				C. D. Saudek, R. L. Derr, and R. R. Kalyani Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A1c JAMA, April 12, 2006; 295(14): 1688 - 1697. [Abstract] [Full Text] [PDF]

				J. B. McGill, T. G. Cole, W. Nowatzke, S. Houghton, E. B. Ammirati, T. Gautille, and M. J. Sarno Circulating 1,5-Anhydroglucitol Levels in Adult Patients With Diabetes Reflect Longitudinal Changes of Glycemia: A U.S. trial of the GlycoMark assay Diabetes Care, August 1, 2004; 27(8): 1859 - 1865. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden European Association for the Study of Diabetes (EASD) 2001 Meeting Diabetes Care, July 1, 2002; 25(7): 1229 - 1236. [Full Text] [PDF]

				D. Stickle and J. Turk A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control Am J Physiol Endocrinol Metab, October 1, 1997; 273(4): E821 - E830. [Abstract] [Full Text] [PDF]